Oncological outcomes of I125 low dose brachytherapy in localized prostate cancer
Canadian Journal of Urology · 2026 · 33 (1) · 93-103
DOI: 10.32604/cju.2026.069182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Urology, 2026. Verfasst von Gilberto Chéchile Toniolo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Médico Tecnológico and Prostate Institute, Barcelona, 08028, Spain. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Brachytherapy, Iodine Radioisotopes. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND: Low-dose rate (LDR) prostate brachytherapy is a recommended treatment of localized prostate cancer in current guidelines. The study aimed to determine biochemical relapse-free survival (BRFS) in patients treated with dynamic real-time low-dose rate (LDR) brachytherapy using Iodine 125 (I125). METHODS: We retrospectively reviewed 499 patients with localized prostate cancer treated with I125 LDR real-time brachytherapy between 2003 and 2021. The mean patient age was 65 years (range: 45-84 years). Based on the National Comprehensive Cancer Network (NCCN) risk classification, 230 patients (46.1%) were categorized as low risk, 235 (47.1%) as intermediate risk, and 34 (6.8%) as high risk. Gleason scores were distributed as follows: 3+3 in 283 cases (56.7%), 3+4 in 157 cases (31.5%), 4+3 in 46 cases (9.2%), and 4+4 in 13 cases (2.6%). The mean follow-up was 70.5 months. RESULTS: Tumor relapse was observed in 47 patients (9.4%) over a mean follow-up period of 6.26 years (SD 4.16). Local recurrence within the prostate occurred in 20 cases (4%). Patients with nadir PSA 0.2 ng/mL (21.9%) (p = 0.0001). Biochemical relapse-free (BRFS) rates at 5, 10 and 15 years were 96%, 91.5% and 88.9%, respectively. When stratified by NCCCN risk groups, 5-year BRFS was 96% in low risk, 98% in intermediate risk and 85% in high risk patients (p = 0.003). In multivariate analysis, only age at the time of brachytherapy (p = 0.009), initial PSA (p = 0.007) and Gleason grade (p = 0.007) were significantly associated with tumor recurrence. Cancer-specific survival and overall survival were 99.8% and 98.0%, respectively. CONCLUSIONS: LDR with I125 has excellent long-term oncological outcomes for patients with low and intermediate-risk prostate cancer, in particular, patients achieving a nadir PSA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto Médico Tecnológico and Prostate Institute, Barcelona, 08028, Spain.
- Statistics Department, Universidad Nacional de Córdoba, Córdoba, 5000, Argentina.
Zitieren
APA
Chéchile Toniolo, G., Jornet, N., Rojas, J., Tejedor, N., Carrara, S., Maccagno, A., & Brufau, T. (2026). Oncological outcomes of I125 low dose brachytherapy in localized prostate cancer. Canadian Journal of Urology, 33(1), 93-103. https://doi.org/10.32604/cju.2026.069182
Vancouver
Chéchile Toniolo G, Jornet N, Rojas J, Tejedor N, Carrara S, Maccagno A, et al. Oncological outcomes of I125 low dose brachytherapy in localized prostate cancer. Canadian Journal of Urology. 2026;33(1):93-103. doi:10.32604/cju.2026.069182
BibTeX
@article{ChchileToniolo2026,
author = {Chéchile Toniolo, Gilberto and Jornet, Nuria and Rojas, Jady and Tejedor, Natalia and Carrara, Santiago and Maccagno, Alicia and Brufau, Teresa},
title = {Oncological outcomes of I125 low dose brachytherapy in localized prostate cancer},
journal = {Canadian Journal of Urology},
year = {2026},
volume = {33},
number = {1},
pages = {93--103},
doi = {10.32604/cju.2026.069182}
}
EUVIMED